title: Immunogenicity of repeated Sendai viral vector vaccination in macaques.
abstract: Induction of durable cellular immune responses by vaccination is an important strategy for the control of persistent pathogen infection. Viral vectors are promising vaccine tools for eliciting antigen-specific T-cell responses. Repeated vaccination may contribute to durable memory T-cell induction, but anti-vector antibodies could be an obstacle to its efficacy. We previously developed a Sendai virus (SeV) vector vaccine and showed the potential of this vector for efficient T-cell induction in macaques. Here, we examined whether repeated SeV vector vaccination with short intervals can enhance antigen-specific CD8(+) T-cell responses. Four rhesus macaques possessing the MHC-I haplotype 90-120-Ia were immunized three times with intervals of three weeks. For the vaccination, we used replication-defective F-deleted SeV vectors inducing CD8(+) T-cell responses specific for simian immunodeficiency virus Gag(206-216) and Gag(241-249), which are dominant epitopes restricted by 90-120-Ia-derived MHC-I molecules. All four animals showed higher Gag(206-216)-specific and Gag(241-249)-specific CD8(+) T-cell responses after the third vaccination than those after the first vaccination, indicating enhancement of antigen-specific CD8(+) T-cell responses by the second/third SeV vector vaccination even with short intervals. These results suggest that repeated SeV vector vaccination can contribute to induction of efficient and durable T-cell responses.
authors.affiliation: AIDS Research Center, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Kurihara
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Takahara
authors.forename: Takushi
authors.initials: T
authors.lastname: Nomura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishii
authors.forename: Nami
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Naofumi
authors.initials: N
authors.lastname: Takahashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Inoue
authors.forename: Akihiro
authors.initials: A
authors.lastname: Iida
authors.forename: Hiroto
authors.initials: H
authors.lastname: Hara
authors.forename: Tsugumine
authors.initials: T
authors.lastname: Shu
authors.forename: Mamoru
authors.initials: M
authors.lastname: Hasegawa
authors.forename: Chikaya
authors.initials: C
authors.lastname: Moriya
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Matano
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000235:genetics / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000276:immunology; D007117:Immunization, Secondary; D008253:Macaca mulatta; D011993:Recombinant Fusion Proteins; D018449:SAIDS Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D029082:Sendai virus / Q000235:genetics / Q000276:immunology; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000956:Antigens, Viral; D015683:Gene Products, gag; D011993:Recombinant Fusion Proteins; D018449:SAIDS Vaccines